Biosurgery: Technologies and Global Markets

Biosurgery: Technologies and Global Markets

  • January 2017
  • 192 pages
  • BCC Research
Report ID: 4683545
Report Highlights
The global biosurgery market should reach $12.5 billion by 2021 from $8.3 billion in 2016 at a compound annual growth rate (CAGR) of 8.5%, from 2016 to 2021.

Report Includes
- An overview of the global market for biosurgery.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Segmentation of the market on the basis of product type, source, application, and region.
- In depth coverage of the market dynamics, technology trends, drivers, constraints, and key strategies.
- Discussion of government regulations, medical associations & international regulatory agencies.
- Analysis of patents pertaining to biosurgery.
- Profiles of companies related to the industry.

Report Scope
This report analyzes the market for products used to reduce excessive hemorrhage during surgery. In a surgical procedure, these products are used as adhesion agents to seal wounds and to repair damaged or weakened tissue. This report does not consider the revenue associated with the main surgery cost; rather, it considers the revenue spent on stoppage/minimization of damage to the adjacent tissue to minimize intraoperative and postoperative complications. Due to their ease of application, these products improve the work efficiency of surgeons. Biosurgery products can be used to disinfect wounds with the help of maggots, and are used particularly for chronic infected wounds, which do not get treated by antibiotics. This report covers all of the existing applications of biosurgery products.

The global biosurgery market is segmented primarily by product type, application, source, and region. Biosurgery products are segmented by type into anti-adhesive agents, hemostatic agents, surgical sealing agents, bone-graft substitutes, and soft-tissue management. The application segments include cardiothoracic surgery, neurosurgery and spine surgery, orthopedic surgery, and general surgery. Based on source, the biosurgery market is segmented into biological and synthetic products.

An in-depth analysis of these segments is given in this report. The report also provides a detailed qualitative account of the market dynamics, technology trends, key strategies, and regulatory scenario.

The market is segmented by region into North America, Europe, Asia-Pacific, and ROW, including further division into key countries. Companies profiled in this report include Johnson & Johnson (Ethicon) Baxter International Inc., Zimmer Biomet Holdings Inc., Wright Medical Group NV, C.R. Bard Inc., Medtronic Plc, Tissuemed Ltd., CryoLife Inc., Hemostasis LLC, Cohera Medical Inc., Kuros Biosciences, B. Braun Melsungen AG, Sanofi SA, Stryker Corp., Exactech Inc., Z-Medica Corp., RTI Surgical, Smith & Nephew Plc, and HyperBranch Medical Technology Inc.
CHAPTER 1
INTRODUCTION 2
STUDY OBJECTIVES 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
SOURCE OF INFORMATION AND METHODOLOGY 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL BIOSURGERY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL BIOSURGERY MARKET, BY REGION, 2015-2021 ($ MILLIONS) 8
CHAPTER 3 MARKET OVERVIEW 10
MARKET EVOLUTION AND INNOVATION 10
MERITS OF BIOSURGERY PROCEDURES 10
FIGURE 1 DIFFERENT TYPES OF BIOSURGERY THERAPIES 10
BONE-GRAFT SUBSTITUTE THERAPY 11
BIOLOGICAL HEMOSTATS THERAPY 12
BIOLOGICAL SEALANTS AND ANTI-ADHESIVE THERAPY 12
FIGURE 2 TIMELINE OF FIBRIN SEALANTS 12
BIOMESH THERAPY 13
MAGGOT THERAPY 14
GOVERNMENT REGULATIONS, MEDICAL ASSOCIATIONS, AND INTERNATIONAL REGULATORY AGENCIES 14
RULES AND REGULATIONS SCENARIO IN THE U.S. 14
TABLE 1 MEDICAL DEVICE CLASSIFICATION 14
Pre-Market Approval (PMA) 15
PMA Supplements 15
TABLE 2 TYPES OF PMA SUPPLEMENTS 15
510(k) Notification 16
Traditional 510(k) 16
RULES AND REGULATIONS SCENARIO IN THE EUROPEAN UNION 16
TABLE 3 MEDICAL DEVICES BY CLASS 17
RULES AND REGULATIONS SCENARIO IN CHINA 17
RULES AND REGULATIONS SCENARIO IN JAPAN 18
TABLE 4 RULES AND REGULATIONS SCENARIO IN JAPAN 18
DEMOGRAPHICS, INCIDENCE AND PREVALENCE RATES, AND OTHER FACTORS INFLUENCING BIOSURGERY MARKET GROWTH 19
AGING POPULATION 20
INCREASING PREVALENCE OF CHRONIC DISORDERS GLOBALLY 20
FIGURE 3 ESTIMATED PERCENT OF DEATHS CAUSED BY CHRONIC DISORDERS, 2020 (%) 20
FIGURE 4 NUMBER OF DEATHS CAUSED BY SEVERE CHRONIC DISORDER OR TRAUMA, 2012 (MILLIONS) 21
INCREASING HEALTHCARE EXPENDITURE 22
FIGURE 5 TOP COUNTRIES FOR HEALTH EXPENDITURES PER CAPITA ($) 22
CLINICAL GUIDELINES AND REIMBURSEMENT SCENARIO 23
U.S. HEALTHCARE STRUCTURAL CHARACTERISTICS 23
The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (H.R. 1130, S. 598) 23
Medicare 23
Other Issues 23
TECHNOLOGY TRENDS 23
3-D TISSUE ASSEMBLY 23
BIO-THYROID 24
Expected Advantages of a Bio-Thyroid 25
PATENTS IN BIOMATERIALS 25
TABLE 5 MIMEDX: PATENT PORTFOLIO 25
BIOSURGERY PIPELINE 25
FIGURE 6 PIPELINE OF BIOSURGICAL PRODUCTS 25
NOVEL TECHNOLOGIES FOR THE FUTURE OF BIOSURGERY 27
3-D BIO-PRINTING 27
Direct Organ Manufacturing 27
BIO-PRINTING TISSUES AND ORGANS 28
MEDICAL ADVANTAGES OF 3-D PRINTING IN BIOSURGERY 28
Customization and Personalization 28
Bio-Printing Tissues and Organs 28
Customized Implants and Prostheses 28
BIO-PRINTERS 28
KEY STRATEGIES 29
FIGURE 7 KEY STRATEGIES IN BIOSURGERY MARKET (%) 29
MARKET DYNAMICS 31
DRIVERS 31
Increase in the Incidence of Chronic Diseases 31
Increasing Geriatric Population 32
FIGURE 8 GLOBAL LIFE EXPECTANCY OF GERIATRIC POPULATION, 2010-2050 32
Increase in the Obese and Overweight Population 33
Advantages of Biosurgery over Traditional Surgical Methods 34
RESTRAINTS 35
High Costs 35
Lack of Awareness and Societal Disapproval 35
Popularity of Minimally Invasive Surgeries 36
OPPORTUNITIES 36
Improvement in Healthcare Infrastructure 36
Presence of Multifunctional Products 37
CHAPTER 4 BIOSURGERY MARKET BY PRODUCT TYPE 39
FIGURE 9 DIFFERENT TYPES OF NATURAL BIOSURGICAL SEALANTS 39
TABLE 6 GLOBAL BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 40
ANTI-ADHESIVE AGENTS 40
ANTI-ADHESIVE AGENTS BY APPLICATION 42
Pharmacological Agents 42
Barrier Agents 42
Hydro-Floatation Agents 43
Solid-Barrier Anti-Adhesive Agents 44
TABLE 7 GLOBAL MARKET FOR ANTI-ADHESIVE AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 44
HEMOSTATIC AGENTS 44
TYPES OF HEMOSTATIC AGENTS 45
Mechanical Hemostatic Agents 45
Thermal Based-Energy Hemostatic Agents 46
Chemical Hemostatic Agents 46
Topical Hemostatic Agents 46
Passive Hemostatic Agents 47
Active Hemostatic Agents 48
Flowable Products 48
TABLE 8 GLOBAL MARKET FOR HEMOSTATIC AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 49
SURGICAL SEALING AGENTS 49
TABLE 9 GLOBAL MARKET FOR SURGICAL SEALING AGENTS BY TYPE, THROUGH 2021 ($ MILLIONS) 49
TABLE 10 GLOBAL MARKET FOR SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 50
SURGICAL SEALING AGENTS AVAILABLE IN THE MARKET 50
TABLE 11 KEY SURGICAL SEALING AGENTS AVAILABLE IN THE MARKET 50
NATURAL SURGICAL SEALING AGENTS 51
TABLE 12 GLOBAL MARKET FOR NATURAL SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 51
Fibrin Sealants or Glues 51
Gelatin-Based Sealants 52
Human Fibrinogen and Thrombin Fleece 52
Oxidized Regenerated Methylcellulose 53
Albumin-Based Sealants 53
Glutaraldehyde-Based Adhesive 53
SYNTHETIC SURGICAL SEALING AGENTS 53
TABLE 13 GLOBAL MARKET FOR SYNTHETIC SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 54
Polyethylene Glycol (PEG) Sealant 54
Cyanoacrylates 55
BONE-GRAFT SUBSTITUTES 55
TABLE 14 GLOBAL MARKET FOR BONE-GRAFT SUBSTITUTES BY REGION, THROUGH 2021 ($ MILLIONS) 55
TABLE 15 DIFFERENT TYPES OF BONE-GRAFT SUBSTITUTES 56
TYPES OF BONE-GRAFT SUBSTITUTES 57
TABLE 16 KEY OSTEOBIOLOGIC PRODUCTS AVAILABLE IN THE MARKET 58
TABLE 17 GLOBAL MARKET FOR BONE-GRAFT SUBSTITUTES BY TYPE, THROUGH 2021 ($ MILLIONS) 59
CELL-BASED MATRICES 60
Trinity Multipotential Cellular Bone Matrix 60
TABLE 18 GLOBAL MARKET FOR CELL-BASED MATRICES BY REGION, THROUGH 2021 ($ MILLIONS) 61
BONE MORPHOGENETIC PROTEINS 61
BMP-2 61
BMP-7 62
TABLE 19 GLOBAL MARKET FOR BONE MORPHOGENETIC PROTEINS BY REGION, THROUGH 2021 ($ MILLIONS) 62
DEMINERALIZED BONE MATRIX 62
FIGURE 10 STEPS INVOLVED IN DOWNSTREAM PROCESSING OF DEMINERALIZED BONE MATRIX (DBM) 63
TABLE 20 GLOBAL MARKET FOR DEMINERALIZED BONE MATRIX BY REGION, THROUGH 2021 ($ MILLIONS) 64
SYNTHETIC GRAFT EXTENDER 65
TABLE 21 COMMON MATERIALS USED TO MANUFACTURE SYNTHETICS 66
TABLE 22 GLOBAL MARKET FOR SYNTHETIC GRAFT EXTENDERS BY REGION, THROUGH 2021 ($ MILLIONS) 66
SOFT-TISSUE MANAGEMENT/MESH/PATCH 67
TABLE 23 GLOBAL MARKET FOR SOFT-TISSUE PATCH/MESH BY TYPE, THROUGH 2021 ($ MILLIONS) 67
TABLE 24 GLOBAL MARKET FOR SOFT-TISSUE PATCH/MESH BY REGION, THROUGH 2021 ($ MILLIONS) 67
TYPES OF SOFT TISSUE-MANAGEMENT MESH/PATCH 68
TABLE 25 KEY SOFT TISSUE-MANAGEMENT PRODUCTS AVAILABLE IN THE MARKET 68
TABLE 26 KEY SURGICAL MESHES AVAILABLE IN THE MARKET 69
Natural Mesh/Patch 69
TABLE 27 GLOBAL MARKET FOR NATURAL MESH/PATCH BY REGION, THROUGH 2021 ($ MILLIONS) 70
TABLE 28 TYPES OF NATURAL MESHES 72
Synthetic Mesh/Patch 72
TABLE 29 GLOBAL MARKET FOR SYNTHETIC MESH/PATCH BY REGION, THROUGH 2021 ($ MILLIONS) 73
TABLE 30 TYPES OF SYNTHETIC MESHES 74
CHAPTER 5 BIOSURGERY MARKET BY APPLICATION 76
TABLE 31 GLOBAL MARKET FOR BIOSURGERY BY APPLICATION, THROUGH 2021 ($ MILLIONS) 76
CARDIOTHORACIC SURGERY 77
TABLE 32 GLOBAL BIOSURGERY MARKET FOR CARDIO AND THORACIC SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 78
FIGURE 11 BONE GRAFTS: PROCESS FLOWCHART 78
TABLE 33 TYPES OF CARDIOVASCULAR DISEASES 79
CARDIOVASCULAR DISEASE RISK FACTORS 80
COMMON SYMPTOMS OF CARDIOVASCULAR DISEASES 80
SYMPTOMS OF RHEUMATIC HEART DISEASE 81
NEUROSURGERY AND SPINE SURGERY 82
TABLE 34 GLOBAL BIOSURGERY MARKET FOR NEURO AND SPINE SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 82
ORTHOPEDIC SURGERY 83
TABLE 35 GLOBAL BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 83
REVISION HIP ARTHROPLASTY 84
PEDIATRICS 85
TRAUMA SURGERY 85
SPORTS MEDICINE 86
TABLE 36 STAGES OF GRAFT HEALING AND THEIR CHARACTERISTICS 86
GENERAL SURGERY 86
TABLE 37 GLOBAL BIOSURGERY MARKET FOR GENERAL SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 87
INCIDENCE RATES OF SURGICAL PROCEDURES AND ANALYSIS 92
CHAPTER 6 BIOSURGERY MARKET BY SOURCE 95
TABLE 38 GLOBAL MARKET FOR BIOSURGERY PRODUCTS BY SOURCE TYPE, THROUGH 2021 ($ MILLIONS) 95
NATURAL/BIOLOGICAL PRODUCTS 96
TABLE 39 GLOBAL BIOSURGERY MARKET FOR NATURAL PRODUCT SOURCES BY REGION, THROUGH 2021 ($ MILLIONS) 96
FIBRIN-BASED PRODUCTS 97
ALBUMIN-BASED PRODUCTS 98
THROMBIN-BASED PRODUCTS 99
COLLAGEN-BASED PRODUCTS 101
GELATIN-BASED PRODUCTS 102
SYNTHETIC PRODUCTS 102
TABLE 40 GLOBAL BIOSURGERY MARKET FOR SYNTHETIC PRODUCT SOURCES BY REGION, THROUGH 2021 ($ MILLIONS) 103
POLYETHYLENE GLYCOL POLYMER-BASED PRODUCTS 103
CYANOACRYLATE-BASED PRODUCTS 105
BIODEGRADABLE MATERIALS 106
NONBIODEGRADABLE MATERIAL 108
CHAPTER 7 COMPETITIVE LANDSCAPE 111
TABLE 41 KEY COMPETITIVE STRATEGIES, 2014-2016 (NUMBER/%) 111
FIGURE 12 KEY COMPETITIVE STRATEGIES, 2014-2016 (%) 112
PRODUCT DEVELOPMENT 112
TABLE 42 PRODUCT DEVELOPMENT STRATEGY BY COMPANY, 2014-2016 (NUMBER/%) 113
FIGURE 13 PRODUCT DEVELOPMENT STRATEGY BY COMPANY, 2014-2016 (%) 113
TABLE 43 LIST OF KEY PRODUCT DEVELOPMENTS ANNOUNCED, 2014-2016 114
AGREEMENT 116
TABLE 44 AGREEMENT STRATEGY BY COMPANY, 2014-2016 (NUMBER/%) 117
FIGURE 14 AGREEMENT STRATEGY BY COMPANY, 2014-2016 (%) 117
TABLE 45 LIST OF KEY AGREEMENTS ANNOUNCED, 2014-2016 118
ACQUISITION 119
TABLE 46 ACQUISITIONS OR MERGERS BY COMPANY, 2014-2016 (NUMBER/%) 120
FIGURE 15 ACQUISITION STRATEGY BY COMPANY, 2014-2016 (%) 120
TABLE 47 LIST OF KEY ACQUISITIONS ANNOUNCED, 2014-2016 121
EXPANSION 121
TABLE 48 EXPANSIONS BY COMPANY, 2014-2016 (NUMBER/%) 122
FIGURE 16 EXPANSION STRATEGY BY COMPANY, 2014-2016 (%) 122
TABLE 49 LIST OF KEY EXPANSIONS, 2014-2016 123
CHAPTER 8 BIOSURGERY MARKET BY REGION 125
TABLE 50 GLOBAL BIOSURGERY MARKET BY REGION, THROUGH 2021 ($ MILLIONS) 125
FIGURE 17 GLOBAL MARKET FOR BIOSURGERY BY REGION, 2015 (%) 125
FIGURE 18 TOP COUNTRIES FOR AESTHETIC SURGICAL PROCEDURES, 2014 (%) 126
FIGURE 19 PATENTS GRANTED BY DIFFERENT ORGANIZATIONS IN BIOSURGERY RESEARCH, 2015 (%) 127
FIGURE 20 TOP COMPANIES RECEIVING PATENTS FOR BIOMATERIALS IN 2015 (%) 128
NORTH AMERICA 129
TABLE 51 NORTH AMERICAN BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 129
FIGURE 21 NORTH AMERICAN SHARE OF BIOSURGERY MARKET BY COUNTRY, 2015 (%) 129
TABLE 52 NORTH AMERICAN BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 130
FIGURE 22 NORTH AMERICA R &D INVESTMENT, 2014 (%) 131
U.S. 131
FIGURE 23 DIABETES PREVALENCE AMONG DIFFERENT AMERICAN ETHNICITIES (%) 132
CANADA 133
FIGURE 24 CANADA MEDICAL DEVICE MARKET, 2012 (%) 133
TABLE 53 TOP 10 CANADIAN MEDICAL DEVICE EXPORTS, 2012 ($/%) 134
MEXICO 135
EUROPE 135
TABLE 54 EUROPEAN BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 135
TABLE 55 EUROPEAN BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 135
FIGURE 25 EUROPEAN BIOSURGERY MARKET BY COUNTRY, 2015 (%) 136
FIGURE 26 BREAKDOWN OF CHRONIC DISORDERS IN EUROPE, 2015 (%) 136
EUROPEAN UNION INVESTMENT SCENARIO 138
FIGURE 27 ESTIMATED EUROPEAN UNION EXPENDITURE ON RESEARCH, DEVELOPMENT AND INNOVATION, 2014-2020 (%) 138
EU HEALTH PROGRAM 2014-2020 138
INNOVATIVE MEDICINES INITIATIVE PROGRAM 139
U.K. 140
FIGURE 28 FLOW OF FUNDS BETWEEN THE U.K. AND EUROPEAN UNION, 2007-2013 (%) 140
GERMANY 141
FIGURE 29 DEATHS PER 100,000 FROM HEART DISEASE IN 2013 (NUMBER) 141
FRANCE 142
REST OF EUROPE 143
ASIA-PACIFIC 143
TABLE 56 ASIA-PACIFIC BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 144
TABLE 57 ASIA-PACIFIC BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 144
FIGURE 30 ASIA-PACIFIC BIOSURGERY MARKET BY COUNTRY, 2015 (%) 144
CHINA 145
FIGURE 31 BREAKDOWN OF CHRONIC DISORDERS IN CHINA (2014) (%) 146
INDIA 147
FIGURE 32 TOTAL NUMBER OF DEATHS IN INDIA FROM CHRONIC DISORDERS, 2015-2020 (MILLIONS) 148
FIGURE 33 PERCENTAGE OF CARDIOVASCULAR PATIENTS BY AREA IN INDIA, 2013 (%) 149
JAPAN 150
FIGURE 34 STRATIFICATION OF GERIATRIC POPULATION STATISTICS, BY AGE IN JAPAN (%) 150
AUSTRALIA 151
REST OF ASIA 152
REST OF WORLD 153
TABLE 58 REST OF WORLD BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 153
FIGURE 35 REST OF WORLD BIOSURGERY MARKET BY COUNTRY, 2015 (%) 153
TABLE 59 REST OF WORLD BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 154
LATIN AMERICA 154
CHAPTER 9 PATENT ANALYSIS 156
FIGURE 36 PATENTS REGISTERED/APPROVED WORLDWIDE, 2010-2016 (%) 156
U.S. PATENT ANALYSIS 157
BY PRODUCT TYPE 157
FIGURE 37 U.S. PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 157
BY MARKET PARTICIPANTS 157
FIGURE 38 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 158
EUROPE PATENT ANALYSIS 158
BY PRODUCT TYPE 158
FIGURE 39 EUROPE PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 159
BY MARKET PARTICIPANTS 159
FIGURE 40 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 159
JAPAN PATENT ANALYSIS 160
BY PRODUCT TYPE 160
FIGURE 41 JAPAN PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 160
BY MARKET PARTICIPANTS 161
FIGURE 42 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 161
CHINA PATENT ANALYSIS 162
BY PRODUCT TYPE 162
FIGURE 43 CHINA PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 162
BY MARKET PARTICIPANTS 163
FIGURE 44 CHINA PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 163
KOREA PATENT ANALYSIS 164
BY PRODUCT TYPE 164
FIGURE 45 KOREA PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 164
BY MARKET PARTICIPANTS 165
FIGURE 46 KOREA PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 165
CHAPTER 10 COMPANY PROFILES 167
B. BRAUN MELSUNGEN AG 167
BIOSURGERY PRODUCT PORTFOLIO 167
TABLE 60 B. BRAUN: RECENT DEVELOPMENTS, 2014-2016 167
TABLE 61 B. BRAUN: FINANCIALS, 2013-2015 ($ MILLIONS/%) 168
BAXTER INTERNATIONAL INC. 168
BIOSURGERY PRODUCT PORTFOLIO 168
TABLE 62 BAXTER: RECENT DEVELOPMENTS, 2014-2016 169
TABLE 63 BAXTER: FINANCIALS, 2013-2015 ($ MILLIONS/%) 169
CERAPEDICS INC. 169
BIOSURGERY PRODUCT PORTFOLIO 170
TABLE 64 CERAPEDICS INC.: RECENT DEVELOPMENTS, 2014-2016 170
COHERA MEDICAL INC. 170
BIOSURGERY PRODUCT PORTFOLIO 170
TABLE 65 COHERA: RECENT DEVELOPMENTS, 2014-2016 171
C.R. BARD INC. 171
BIOSURGERY PRODUCT PORTFOLIO 171
TABLE 66 C.R. BARD: RECENT DEVELOPMENTS, 2014-2016 172
TABLE 67 C.R. BARD: FINANCIALS, 2013-2015 ($ MILLIONS/%) 172
CRYOLIFE INC. 172
BIOSURGERY PRODUCT PORTFOLIO 173
TABLE 68 CRYOLIFE: RECENT DEVELOPMENTS, 2014-2016 173
TABLE 69 CRYOLIFE: FINANCIALS, 2013-2015 ($ MILLIONS/%) 173
EXACTECH INC. 173
BIOSURGERY PRODUCT PORTFOLIO 174
TABLE 70 EXATECH INC.: RECENT DEVELOPMENTS, 2014-2016 174
TABLE 71 EXATECH INC. FINANCIALS, 2013-2015 ($ MILLIONS/%) 175
HEMOSTASIS LLC 175
BIOSURGERY PRODUCT PORTFOLIO 175
HYPERBRANCH MEDICAL TECHNOLOGY INC. 175
BIOSURGERY PRODUCT PORTFOLIO 176
TABLE 72 HYPERBRANCH MEDICAL TECHNOLOGY: RECENT DEVELOPMENTS, 2014-2016 176
JOHNSON & JOHNSON 176
BIOSURGERY PRODUCT PORTFOLIO 177
TABLE 73 JOHNSON & JOHNSON: RECENT DEVELOPMENTS, 2014-2016 177
TABLE 74 JOHNSON & JOHNSON: FINANCIALS, 2013-2015 ($ MILLIONS/%) 178
KUROS BIOSCIENCES AG 178
BIOSURGERY PRODUCT PORTFOLIO 178
TABLE 75 KUROS BIOSCIENCES: RECENT DEVELOPMENTS, 2014-2016 178
TABLE 76 KUROS BIOSCIENCES: FINANCIALS, 2013-2015 ($ MILLIONS/%) 179
MEDTRONIC PLC 179
BIOSURGERY PRODUCT PORTFOLIO 179
TABLE 77 MEDTRONIC: RECENT DEVELOPMENTS, 2014-2016 180
TABLE 78 MEDTRONIC: FINANCIALS, 2014-2016 ($ MILLIONS/%) 180
RTI SURGICAL 180
BIOSURGERY PRODUCT PORTFOLIO 181
TABLE 79 RTI SURGICAL: RECENT DEVELOPMENTS, 2014-2016 181
TABLE 80 RTI SURGICAL: FINANCIALS, 2013-2015 ($ MILLIONS/%) 181
SANOFI SA 182
BIOSURGERY PRODUCT PORTFOLIO 182
TABLE 81 SANOFI SA: RECENT DEVELOPMENTS, 2014-2016 182
TABLE 82 SANOFI SA: FINANCIALS, 2013-2015 ($ MILLIONS/%) 182
SMITH & NEPHEW PLC 183
BIOSURGERY PRODUCT PORTFOLIO 183
TABLE 83 SMITH & NEPHEW: RECENT DEVELOPMENTS, 2014-2016 183
TABLE 84 SMITH & NEPHEW: FINANCIALS, 2013-2015 ($ MILLIONS/%) 184
STRYKER CORP. 184
BIOSURGERY PRODUCT PORTFOLIO 184
TABLE 85 STRYKER CORP.: RECENT DEVELOPMENTS, 2011-2016 185
TABLE 86 STRYKER CORP.: FINANCIALS, 2013-2015 ($ MILLIONS/%) 185
TISSUEMED LTD. 185
BIOSURGERY PRODUCT PORTFOLIO 186
TABLE 87 TISSUEMED: RECENT DEVELOPMENTS, 2014-2016 186
TABLE 88 TISSUEMED: FINANCIALS, 2013-2015 ($ MILLIONS/%) 186
WRIGHT MEDICAL GROUP NV 187
BIOSURGERY PRODUCT PORTFOLIO 187
TABLE 89 WRIGHT: RECENT DEVELOPMENTS, 2014-2016 187
TABLE 90 WRIGHT: FINANCIALS, 2013-2015 ($ MILLIONS/%) 188
Z-MEDICA CORP. 188
BIOSURGERY PRODUCT PORTFOLIO 188
TABLE 91 Z-MEDICA: RECENT DEVELOPMENTS, 2014-2016 188
ZIMMER BIOMET HOLDINGS INC. 189
BIOSURGERY PRODUCT PORTFOLIO 189
TABLE 92 ZIMMER BIOMET HOLDINGS INC.: RECENT DEVELOPMENTS, 2014-2016 190
TABLE 93 ZIMMER BIOMET HOLDINGS INC.: FINANCIALS, 2013-2015 ($ MILLIONS/%) 190
CHAPTER 11 APPENDIX 192
TABLE 94 LIST OF PATENTS: U.S. 192
TABLE 95 LIST OF PATENTS: CHINA 197
TABLE 96 LIST OF PATENTS: JAPAN 199
TABLE 97 LIST OF PATENTS: EUROPE 199
TABLE 98 LIST OF PATENTS: KOREA 201


LIST OF TABLES
SUMMARY TABLE GLOBAL BIOSURGERY MARKET, BY REGION, THROUGH 2021 ($ MILLIONS) 8
TABLE 1 MEDICAL DEVICE CLASSIFICATION 14
TABLE 2 TYPES OF PMA SUPPLEMENTS 15
TABLE 3 MEDICAL DEVICES BY CLASS 17
TABLE 4 RULES AND REGULATIONS SCENARIO IN JAPAN 18
TABLE 5 MIMEDX: PATENT PORTFOLIO 25
TABLE 6 GLOBAL BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 40
TABLE 7 GLOBAL MARKET FOR ANTI-ADHESIVE AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 44
TABLE 8 GLOBAL MARKET FOR HEMOSTATIC AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 49
TABLE 9 GLOBAL MARKET FOR SURGICAL SEALING AGENTS BY TYPE, THROUGH 2021 ($ MILLIONS) 49
TABLE 10 GLOBAL MARKET FOR SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 50
TABLE 11 KEY SURGICAL SEALING AGENTS AVAILABLE IN THE MARKET 50
TABLE 12 GLOBAL MARKET FOR NATURAL SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 51
TABLE 13 GLOBAL MARKET FOR SYNTHETIC SURGICAL SEALING AGENTS BY REGION, THROUGH 2021 ($ MILLIONS) 54
TABLE 14 GLOBAL MARKET FOR BONE-GRAFT SUBSTITUTES BY REGION, THROUGH 2021 ($ MILLIONS) 55
TABLE 15 DIFFERENT TYPES OF BONE-GRAFT SUBSTITUTES 56
TABLE 16 KEY OSTEOBIOLOGIC PRODUCTS AVAILABLE IN THE MARKET 58
TABLE 17 GLOBAL MARKET FOR BONE-GRAFT SUBSTITUTES BY TYPE, THROUGH 2021 ($ MILLIONS) 59
TABLE 18 GLOBAL MARKET FOR CELL-BASED MATRICES BY REGION, THROUGH 2021 ($ MILLIONS) 61
TABLE 19 GLOBAL MARKET FOR BONE MORPHOGENETIC PROTEINS BY REGION, THROUGH 2021 ($ MILLIONS) 62
TABLE 20 GLOBAL MARKET FOR DEMINERALIZED BONE MATRIX BY REGION, THROUGH 2021 ($ MILLIONS) 64
TABLE 21 COMMON MATERIALS USED TO MANUFACTURE SYNTHETICS 66
TABLE 22 GLOBAL MARKET FOR SYNTHETIC GRAFT EXTENDERS BY REGION, THROUGH 2021 ($ MILLIONS) 66
TABLE 23 GLOBAL MARKET FOR SOFT-TISSUE PATCH/MESH BY TYPE, THROUGH 2021 ($ MILLIONS) 67
TABLE 24 GLOBAL MARKET FOR SOFT-TISSUE PATCH/MESH BY REGION, THROUGH 2021 ($ MILLIONS) 67
TABLE 25 KEY SOFT TISSUE-MANAGEMENT PRODUCTS AVAILABLE IN THE MARKET 68
TABLE 26 KEY SURGICAL MESHES AVAILABLE IN THE MARKET 69
TABLE 27 GLOBAL MARKET FOR NATURAL MESH/PATCH BY REGION, THROUGH 2021 ($ MILLIONS) 70
TABLE 28 TYPES OF NATURAL MESHES 72
TABLE 29 GLOBAL MARKET FOR SYNTHETIC MESH/PATCH BY REGION, THROUGH 2021 ($ MILLIONS) 73
TABLE 30 TYPES OF SYNTHETIC MESHES 74
TABLE 31 GLOBAL MARKET FOR BIOSURGERY BY APPLICATION, THROUGH 2021 ($ MILLIONS) 76
TABLE 32 GLOBAL BIOSURGERY MARKET FOR CARDIO AND THORACIC SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 78
TABLE 33 TYPES OF CARDIOVASCULAR DISEASES 79
TABLE 34 GLOBAL BIOSURGERY MARKET FOR NEURO AND SPINE SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 82
TABLE 35 GLOBAL BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 83
TABLE 36 STAGES OF GRAFT HEALING AND THEIR CHARACTERISTICS 86
TABLE 37 GLOBAL BIOSURGERY MARKET FOR GENERAL SURGERY APPLICATION BY REGION, THROUGH 2021 ($ MILLIONS) 87
TABLE 38 GLOBAL MARKET FOR BIOSURGERY PRODUCTS BY SOURCE TYPE, THROUGH 2021 ($ MILLIONS) 95
TABLE 39 GLOBAL BIOSURGERY MARKET FOR NATURAL PRODUCT SOURCES BY REGION, THROUGH 2021 ($ MILLIONS) 96
TABLE 40 GLOBAL BIOSURGERY MARKET FOR SYNTHETIC PRODUCT SOURCES BY REGION, THROUGH 2021 ($ MILLIONS) 103
TABLE 41 KEY COMPETITIVE STRATEGIES, 2014-2016 (NUMBER/%) 111
TABLE 42 PRODUCT DEVELOPMENT STRATEGY BY COMPANY, 2014-2016 (NUMBER/%) 113
TABLE 43 LIST OF KEY PRODUCT DEVELOPMENTS ANNOUNCED, 2014-2016 114
TABLE 44 AGREEMENT STRATEGY BY COMPANY, 2014-2016 (NUMBER/%) 117
TABLE 45 LIST OF KEY AGREEMENTS ANNOUNCED, 2014-2016 118
TABLE 46 ACQUISITIONS OR MERGERS BY COMPANY, 2014-2016 (NUMBER/%) 120
TABLE 47 LIST OF KEY ACQUISITIONS ANNOUNCED, 2014-2016 121
TABLE 48 EXPANSIONS BY COMPANY, 2014-2016 (NUMBER/%) 122
TABLE 49 LIST OF KEY EXPANSIONS, 2014-2016 123
TABLE 50 GLOBAL BIOSURGERY MARKET BY REGION, THROUGH 2021 ($ MILLIONS) 125
TABLE 51 NORTH AMERICAN BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 129
TABLE 52 NORTH AMERICAN BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 130
TABLE 53 TOP 10 CANADIAN MEDICAL DEVICE EXPORTS, 2012 ($/%) 134
TABLE 54 EUROPEAN BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 135
TABLE 55 EUROPEAN BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 135
TABLE 56 ASIA-PACIFIC BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 144
TABLE 57 ASIA-PACIFIC BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 144
TABLE 58 REST OF WORLD BIOSURGERY MARKET BY PRODUCT, THROUGH 2021 ($ MILLIONS) 153
TABLE 59 REST OF WORLD BIOSURGERY MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS) 154
TABLE 60 B. BRAUN: RECENT DEVELOPMENTS, 2014-2016 167
TABLE 61 B. BRAUN: FINANCIALS, 2013-2015 ($ MILLIONS/%) 168
TABLE 62 BAXTER: RECENT DEVELOPMENTS, 2014-2016 169
TABLE 63 BAXTER: FINANCIALS, 2013-2015 ($ MILLIONS/%) 169
TABLE 64 CERAPEDICS INC.: RECENT DEVELOPMENTS, 2014-2016 170
TABLE 65 COHERA: RECENT DEVELOPMENTS, 2014-2016 171
TABLE 66 C.R. BARD: RECENT DEVELOPMENTS, 2014-2016 172
TABLE 67 C.R. BARD: FINANCIALS, 2013-2015 ($ MILLIONS/%) 172
TABLE 68 CRYOLIFE: RECENT DEVELOPMENTS, 2014-2016 173
TABLE 69 CRYOLIFE: FINANCIALS, 2013-2015 ($ MILLIONS/%) 173
TABLE 70 EXATECH INC.: RECENT DEVELOPMENTS, 2014-2016 174
TABLE 71 EXATECH INC. FINANCIALS, 2013-2015 ($ MILLIONS/%) 175
TABLE 72 HYPERBRANCH MEDICAL TECHNOLOGY: RECENT DEVELOPMENTS, 2014-2016 176
TABLE 73 JOHNSON & JOHNSON: RECENT DEVELOPMENTS, 2014-2016 177
TABLE 74 JOHNSON & JOHNSON: FINANCIALS, 2013-2015 ($ MILLIONS/%) 178
TABLE 75 KUROS BIOSCIENCES: RECENT DEVELOPMENTS, 2014-2016 178
TABLE 76 KUROS BIOSCIENCES: FINANCIALS, 2013-2015 ($ MILLIONS/%) 179
TABLE 77 MEDTRONIC: RECENT DEVELOPMENTS, 2014-2016 180
TABLE 78 MEDTRONIC: FINANCIALS, 2014-2016 ($ MILLIONS/%) 180
TABLE 79 RTI SURGICAL: RECENT DEVELOPMENTS, 2014-2016 181
TABLE 80 RTI SURGICAL: FINANCIALS, 2013-2015 ($ MILLIONS/%) 181
TABLE 81 SANOFI SA: RECENT DEVELOPMENTS, 2014-2016 182
TABLE 82 SANOFI SA: FINANCIALS, 2013-2015 ($ MILLIONS/%) 182
TABLE 83 SMITH & NEPHEW: RECENT DEVELOPMENTS, 2014-2016 183
TABLE 84 SMITH & NEPHEW: FINANCIALS, 2013-2015 ($ MILLIONS/%) 184
TABLE 85 STRYKER CORP.: RECENT DEVELOPMENTS, 2011-2016 185
TABLE 86 STRYKER CORP.: FINANCIALS, 2013-2015 ($ MILLIONS/%) 185
TABLE 87 TISSUEMED: RECENT DEVELOPMENTS, 2014-2016 186
TABLE 88 TISSUEMED: FINANCIALS, 2013-2015 ($ MILLIONS/%) 186
TABLE 89 WRIGHT: RECENT DEVELOPMENTS, 2014-2016 187
TABLE 90 WRIGHT: FINANCIALS, 2013-2015 ($ MILLIONS/%) 188
TABLE 91 Z-MEDICA: RECENT DEVELOPMENTS, 2014-2016 188
TABLE 92 ZIMMER BIOMET HOLDINGS INC.: RECENT DEVELOPMENTS, 2014-2016 190
TABLE 93 ZIMMER BIOMET HOLDINGS INC.: FINANCIALS, 2013-2015 ($ MILLIONS/%) 190
TABLE 94 LIST OF PATENTS: U.S. 192
TABLE 95 LIST OF PATENTS: CHINA 197
TABLE 96 LIST OF PATENTS: JAPAN 199
TABLE 97 LIST OF PATENTS: EUROPE 199
TABLE 98 LIST OF PATENTS: KOREA 201

LIST OF FIGURES
SUMMARY FIGURE GLOBAL BIOSURGERY MARKET, BY REGION, 2015-2021 ($ MILLIONS) 8
FIGURE 1 DIFFERENT TYPES OF BIOSURGERY THERAPIES 10
FIGURE 2 TIMELINE OF FIBRIN SEALANTS 12
FIGURE 3 ESTIMATED PERCENT OF DEATHS CAUSED BY CHRONIC DISORDERS, 2020 (%) 20
FIGURE 4 NUMBER OF DEATHS CAUSED BY SEVERE CHRONIC DISORDER OR TRAUMA, 2012 (MILLIONS) 21
FIGURE 5 TOP COUNTRIES FOR HEALTH EXPENDITURES PER CAPITA ($) 22
FIGURE 6 PIPELINE OF BIOSURGICAL PRODUCTS 25
FIGURE 7 KEY STRATEGIES IN BIOSURGERY MARKET (%) 29
FIGURE 8 GLOBAL LIFE EXPECTANCY OF GERIATRIC POPULATION, 2010-2050 32
FIGURE 9 DIFFERENT TYPES OF NATURAL BIOSURGICAL SEALANTS 39
FIGURE 10 STEPS INVOLVED IN DOWNSTREAM PROCESSING OF DEMINERALIZED BONE MATRIX (DBM) 63
FIGURE 11 BONE GRAFTS: PROCESS FLOWCHART 78
FIGURE 12 KEY COMPETITIVE STRATEGIES, 2014-2016 (%) 112
FIGURE 13 PRODUCT DEVELOPMENT STRATEGY BY COMPANY, 2014-2016 (%) 113
FIGURE 14 AGREEMENT STRATEGY BY COMPANY, 2014-2016 (%) 117
FIGURE 15 ACQUISITION STRATEGY BY COMPANY, 2014-2016 (%) 120
FIGURE 16 EXPANSION STRATEGY BY COMPANY, 2014-2016 (%) 122
FIGURE 17 GLOBAL MARKET FOR BIOSURGERY BY REGION, 2015 (%) 125
FIGURE 18 TOP COUNTRIES FOR AESTHETIC SURGICAL PROCEDURES, 2014 (%) 126
FIGURE 19 PATENTS GRANTED BY DIFFERENT ORGANIZATIONS IN BIOSURGERY RESEARCH, 2015 (%) 127
FIGURE 20 TOP COMPANIES RECEIVING PATENTS FOR BIOMATERIALS IN 2015 (%) 128
FIGURE 21 NORTH AMERICAN SHARE OF BIOSURGERY MARKET BY COUNTRY, 2015 (%) 129
FIGURE 22 NORTH AMERICA R &D INVESTMENT, 2014 (%) 131
FIGURE 23 DIABETES PREVALENCE AMONG DIFFERENT AMERICAN ETHNICITIES (%) 132
FIGURE 24 CANADA MEDICAL DEVICE MARKET, 2012 (%) 133
FIGURE 25 EUROPEAN BIOSURGERY MARKET BY COUNTRY, 2015 (%) 136
FIGURE 26 BREAKDOWN OF CHRONIC DISORDERS IN EUROPE, 2015 (%) 136
FIGURE 27 ESTIMATED EUROPEAN UNION EXPENDITURE ON RESEARCH, DEVELOPMENT AND INNOVATION, 2014-2020 (%) 138
FIGURE 28 FLOW OF FUNDS BETWEEN THE U.K. AND EUROPEAN UNION, 2007-2013 (%) 140
FIGURE 29 DEATHS PER 100,000 FROM HEART DISEASE IN 2013 (NUMBER) 141
FIGURE 30 ASIA-PACIFIC BIOSURGERY MARKET BY COUNTRY, 2015 (%) 144
FIGURE 31 BREAKDOWN OF CHRONIC DISORDERS IN CHINA (2014) (%) 146
FIGURE 32 TOTAL NUMBER OF DEATHS IN INDIA FROM CHRONIC DISORDERS, 2015-2020 (MILLIONS) 148
FIGURE 33 PERCENTAGE OF CARDIOVASCULAR PATIENTS BY AREA IN INDIA, 2013 (%) 149
FIGURE 34 STRATIFICATION OF GERIATRIC POPULATION STATISTICS, BY AGE IN JAPAN (%) 150
FIGURE 35 REST OF WORLD BIOSURGERY MARKET BY COUNTRY, 2015 (%) 153
FIGURE 36 PATENTS REGISTERED/APPROVED WORLDWIDE, 2010-2016 (%) 156
FIGURE 37 U.S. PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 157
FIGURE 38 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 158
FIGURE 39 EUROPE PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 159
FIGURE 40 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 159
FIGURE 41 JAPAN PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 160
FIGURE 42 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 161
FIGURE 43 CHINA PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 162
FIGURE 44 CHINA PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 163
FIGURE 45 KOREA PATENT ANALYSIS BY PRODUCT, 2010-2016 (%) 164
FIGURE 46 KOREA PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016 (%) 165
Country=World Industry=HealthServices ParentIndustry=Healthcare Date=201701 Topic=MarketReport Publisher=BCCResearch Price=5000